Chemical and advanced materials maker Celanese Corporation (CE) has unveiled Hostaform MT SlideX polyoxymethylene (POM), a family of new tribologically modified, medical-grade thermoplastics.
The tribologically modified materials enable the manufacture of medical devices with a low coefficient of friction and wear. The polymer also reduces the amount of squeaking noise produced when a medical device is operated, further improving patient comfort. On the manufacturing side, the material can be processed without external lubrication.
Hostaform MT SlideX POM is competitive substitute to other high-performance, tribologically modified compounds. It combines Celanese medical technology (MT) service package and helps to reduce costs by eliminating the design constraints while simplifying material combinations in complex devices. When compared with alternative products, it also provides considerably lower coefficient of friction in medical devices.
Hostaform MT SlideX POM is more suited for medical applications such as Chronic Obstructive Pulmonary Disease (COPD) and asthma inhalers, injection devices such as insulin pens, surgical instruments and portable diagnostic medical devices, where low friction, wear and medical compliance are required. These new materials can improve design the performance levels of key medical components while providing more comfort to the patients.
The MT service package caters to quality, change control and regulatory compliance in accordance with pharmaceutical and medical industry expectations, based on Celanese’s extensive experience with material supply to the medical market.
Celanese hopes that its customer-focused approach for the materials businesses and the its commercial actions for its technology-enabled businesses will provide it with adequate opportunities to offset other anticipated headwinds.
Celanese currently carries a Zacks Rank #2 (Buy).
Better-ranked stocks in the diversified chemical space worth considering include Innospec Inc. (IOSP), Valhi Inc. (VHI) and Kronos Worldwide, Inc. (KRO). While both Innospec and Valhi sport a Zacks Rank #1 (Strong Buy), Kronos carries a Zacks Rank #2 (Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
To read this article on Zacks.com click here.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
Be the first to comment